Cosmos Health | COSM | Long at $0.54

***Very Risky OTC play***

Cosmos Health COSM is a pharmaceutical and healthcare company focused on developing, manufacturing, and distributing prescription drugs, OTC medicines, nutraceuticals and medical devices. Share price has been diluted in the past, but the CEO is grabbing shares at an unprecedented rate (average around $0.49 for a commitment of $2.2+ million). Doing a little research, two primary catalysts that may move the share price soon are:

• Recent Manufacturing Agreement for PathMuscle: Just days before the latest buys, on approximately January 5, 2026, COSM announced a five-year deal with Greek pharmaceutical distributor Libytec Pharmaceutical S.A. for its subsidiary Cana Laboratories to handle end-to-end manufacturing (including formulation, production, quality control, and packaging) of PathMuscle, a muscle-related medicine. The agreement projects volumes exceeding 1.2 million units, with a minimum of 591,500 units in the first two years alone. This contract is expected to boost revenue through expanded production capacity and could contribute to stock price recovery, with shares rising on the news.
• Upcoming Product Launch: A new product (potentially tied to recent FDA-related announcements or manufacturing expansions) is slated for release in Q1 or Q2 2026, which could serve as a near-term catalyst for growth in the pharmaceutical and nutraceutical segments.

So, I've rolled the dice and jumped in near $0.54, following the insider buying and potential catalyst growth.
Targets into 2028

1. $0.75 (+38.9%)
2. $1.00 (+85.2%)